(Q40765749)

23 September 2017

title

Intravenous immunoglobulin treatment of lupus nephritis (English)

1 reference

23 September 2017

10

Shoenfeld Y

1 reference

23 September 2017

1

Levy Y

1 reference

23 September 2017

2

Sherer Y

1 reference

23 September 2017

8

Langevitz P

1 reference

23 September 2017

3

George J

1 reference

23 September 2017

Rovensky J

4

1 reference

23 September 2017

Lukac J

5

1 reference

23 September 2017

Rauova L

6

1 reference

23 September 2017

Poprac P

7

1 reference

23 September 2017

Fabbrizzi F

9

1 reference

23 September 2017

publication date

1 April 2000

1 reference

Seminars in Arthritis and Rheumatism

23 September 2017

published in

1 reference

23 September 2017

volume

29

1 reference

23 September 2017

issue

5

1 reference

23 September 2017

page(s)

321-327

1 reference

New therapeutic avenues in autoimmunity

23 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

High-dose immunoglobulin therapy in pericarditis caused by SLE

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Pure red cell aplasia associated with systemic lupus erythematosus: remission after a single course of intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Autoimmune multiorgan involvement in elderly men is it SLE?

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Recurrent cerebral infarction and the antiphospholipid syndrome: effect of intravenous gammaglobulin in a patient with systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Treatment of hemolytic anemia and severe thrombocytopenia with high-dose methylprednisolone and intravenous immunoglobulins in SLE

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

IgG therapy in systemic lupus erythematosus--two case reports

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Prolonged remission of SLE-associated polyradiculoneuropathy after a single course of intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Successful treatment of early secondary myelofibrosis in SLE with IVIG

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Glomerulonephritis associated with complete deficiency of the fourth component of complement. Response to intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Improvement of histological and immunological change in steroid and immunosuppressive drug-resistant lupus nephritis by high-dose intravenous gamma globulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

[Rheumatoid purpura and intravenous immunoglobulins]

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

High-dose immunoglobulin therapy for severe IgA nephropathy and Henoch-Schönlein purpura.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Treatment of antineutrophil cytoplasmic autoantibody-positive systemic vasculitis and glomerulonephritis with pooled intravenous gammaglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated systemic vasculitis with high-dose intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Paradoxical and persistent renal impairment in Henoch-Schönlein purpura after high-dose immunoglobulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Intravenous immunoglobulin-induced osmotic nephrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Acute renal failure associated with immunoglobulin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

Osmotic nephrosis due to high-dose immunoglobulin therapy containing sucrose (but not with glycine) in a patient with immunoglobulin A nephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

The effect of intravenous gamma-globulin on the induction of experimental antiphospholipid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2800%2980018-9

7 January 2021

10.1016/S0049-0172(00)80018-9

Identifiers

DOI

1 reference

23 September 2017

1 reference